Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07612254

aPBI Re-irradiation

This study is to determine whether acute treatment-associated adverse events following breast re-irradiation with aPBI are acceptably low and to assess local control following breast re-irradiation with aPBI. An exploratory aim is to assess cosmetic outcomes following breast re-irradiation with aPBI.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Breast Cancer Recurrent

Age range

40 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Dartmouth-Hitchcock Medical Center

Lebanon, New Hampshire, 03756, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients who have histologically-confirmed, second, ipsilateral breast cancer which was diagnosed more than one year after completing breast conserving therapy.
  • Patients must have received prior radiotherapy to the breast
  • Patients must have an intact, involved breast.
  • Patients must meet ASTRO 2023 guidelines for a strong recommendation for partial breast irradiation.
  • Grade 1-2 disease
  • ER-positive histology
  • Tumor size up to 2 cm
  • Patient's age 40 or older
  • Patients who will undergo breast radiation therapy at D-H Lebanon, D-H St. Johnsbury, or Cheshire Medical Center.
  • Patients must have a lumpectomy cavity that can be delineated on CT scan.
  • Patients who are able to provide informed consent.
  • Females of childbearing potential must have a negative urine or serum pregnancy test within 14 days of study entry.
  • Females of childbearing potential must not be pregnant and not lactating and willing to use medically acceptable form of contraception during radiation therapy.

Exclusion criteria

Patients who meet any of the criteria below may NOT participate in this study:

  • Patients who have not received prior radiotherapy to the ipsilateral breast.
  • Patients who do not meet ASTRO 2023 guidelines for a strong recommendation for partial breast irradiation, including those who meet criteria for conditionally recommended, conditionally not recommended, and not recommended for partial breast irradiation.
  • Patients who are < 40 years of age.
  • Patients with breast implants or other breast reconstruction.
  • Patients who received a prior course of aPBI or breast brachytherapy in the ipsilateral breast.
  • Patients who are actively receiving treatment or within 1 year of treatment from another malignancy, excluding non-melanoma skin cancers.
  • Patients who are pregnant.
  • Patients who are unable to provide informed consent.
  • Patients who decline participation in the study.
  • Patients with active systemic lupus erythematosus, or any history of scleroderma, dermatomyositis with active rash are excluded.

Treatment and study plan

Reirradiation

Radiation

aPBI, which is routinely used to treat patients who have previously not been irradiated, with a dose of 30 Gy in 5 fractions using a VMAT technique.

Primary outcomes

  1. Treatment-associated toxicity

    Time frame: Within 1 year

    Acceptably low acute treatment-associated adverse events following breast re-irradiation with aPBI.

Sponsors and collaborators

Lead sponsor

Dartmouth-Hitchcock Medical Center

Other

Registry information

Official study title

REPEAT: RE-irradiation With a Partial brEast, Accelerated Technique: A Single-Center, Multi-site, Prospective, Phase I/II Clinical Trial

Acronym: REPEAT

Important dates

Study start
2026
Primary completion
2032
Study completion
2033
First posted
May 28, 2026
Registry last updated
May 28, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.